WARNINGS O
Use B-OSE_Labeled_AE
In I-OSE_Labeled_AE
Pregnancy I-OSE_Labeled_AE
CLARITHROMYCIN O
SHOULD O
NOT O
BE O
USED O
IN O
PREGNANT B-Not_AE_Candidate
WOMEN O
EXCEPT O
IN O
CLINICAL O
CIRCUMSTANCES O
WHERE O
NO O
ALTERNATIVE O
THERAPY O
IS O
APPROPRIATE O
. O

IF O
PREGNANCY B-NonOSE_AE
OCCURS O
WHILE O
TAKING O
THIS O
DRUG O
, O
THE O
PATIENT O
SHOULD O
BE O
APPRISED O
OF O
THE O
POTENTIAL O
HAZARD B-OSE_Labeled_AE
TO I-OSE_Labeled_AE
THE I-OSE_Labeled_AE
FETUS I-OSE_Labeled_AE
. O

CLARITHROMYCIN O
HAS O
DEMONSTRATED O
ADVERSE B-NonOSE_AE
EFFECTS I-NonOSE_AE
OF I-NonOSE_AE
PREGNANCY I-NonOSE_AE
OUTCOME I-NonOSE_AE
AND/OR O
EMBRYO B-NonOSE_AE
- I-NonOSE_AE
FETAL I-NonOSE_AE
DEVELOPMENT I-NonOSE_AE
IN O
MONKEYS O
, O
RATS O
, O
MICE O
, O
AND O
RABBITS O
AT O
DOSES O
THAT O
PRODUCED O
PLASMA O
LEVELS O
2 O
TO O
17 O
TIMES O
THE O
SERUM O
LEVELS O
ACHIEVED O
IN O
HUMANS O
TREATED O
AT O
THE O
MAXIMUM O
RECOMMENDED O
HUMAN O
DOSES O
. O

( O
See O
PRECAUTIONS O
- O
Pregnancy O
. O
) O

Hepatotoxicity B-OSE_Labeled_AE
Hepatic B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
, O
including O
increased B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
enzymes I-OSE_Labeled_AE
, O
and O
hepatocellular B-OSE_Labeled_AE
and/or O
cholestatic O
hepatitis I-OSE_Labeled_AE
, O
with O
or O
without O
jaundice B-NonOSE_AE
, O
has O
been O
reported O
with O
clarithromycin O
. O

This O
hepatic B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
may O
be O
severe O
and O
is O
usually O
reversible O
. O

In O
some O
instances O
, O
hepatic B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
with O
fatal B-NonOSE_AE
outcome O
has O
been O
reported O
and O
generally O
has O
been O
associated O
with O
serious O
underlying O
diseases O
and/or O
concomitant O
medications O
. O

Discontinue O
clarithromycin O
immediately O
if O
signs O
and O
symptoms O
of O
hepatitis B-NonOSE_AE
occur O
. O

Drug O
Interactions O
Serious O
adverse O
reactions O
have O
been O
reported O
in O
patients O
taking O
clarithromycin O
concomitantly O
with O
CYP3A4 O
substrates O
. O

These O
include O
colchicine B-NonOSE_AE
toxicity I-NonOSE_AE
with O
colchicine O
; O
rhabdomyolysis B-NonOSE_AE
with O
simvastatin O
, O
lovastatin O
, O
and O
atorvastatin O
; O
and O
hypotension B-NonOSE_AE
with O
calcium O
channel O
blockers O
metabolized O
by O
CYP3A4 O
( O
e.g. O
, O
verapamil O
, O
amlodipine O
, O
diltiazem O
) O
( O
see O
CONTRAINDICATIONS O
and O
PRECAUTIONS O
- O
Drug O
Interactions O
) O
. O

Life-threatening O
and O
fatal B-NonOSE_AE
drug B-NonOSE_AE
interactions I-NonOSE_AE
have O
been O
reported O
in O
patients O
treated O
with O
clarithromycin O
and O
colchicine O
. O

Clarithromycin O
is O
a O
strong O
CYP3A4 O
inhibitor O
and O
this O
interaction O
may O
occur O
while O
using O
both O
drugs O
at O
their O
recommended O
doses O
. O

If O
co-administration O
of O
clarithromycin O
and O
colchicine O
is O
necessary O
in O
patients O
with O
normal O
renal O
and O
hepatic O
function O
, O
the O
dose O
of O
colchicine O
should O
be O
reduced O
. O

Patients O
should O
be O
monitored O
for O
clinical O
symptoms O
of O
colchicine B-NonOSE_AE
toxicity I-NonOSE_AE
. O

Concomitant O
administration O
of O
clarithromycin O
and O
colchicine O
is O
contraindicated O
in O
patients O
with O
renal B-Not_AE_Candidate
or O
hepatic O
impairment I-Not_AE_Candidate
( O
see O
CONTRAINDICATIONS O
and O
PRECAUTIONS O
- O
Drug O
Interactions O
) O
. O

Clostridium O
difficile O
Associated O
Diarrhea O
Clostridium B-OSE_Labeled_AE
difficile I-OSE_Labeled_AE
associated I-OSE_Labeled_AE
diarrhea I-OSE_Labeled_AE
( I-OSE_Labeled_AE
CDAD I-OSE_Labeled_AE
) O
has O
been O
reported O
with O
use O
of O
nearly O
all O
antibacterial O
agents O
, O
including O
BIAXIN O
, O
and O
may O
range O
in O
severity O
from O
mild O
diarrhea B-OSE_Labeled_AE
to O
fatal B-NonOSE_AE
colitis B-OSE_Labeled_AE
. O

Treatment O
with O
antibacterial O
agents O
alters O
the O
normal O
flora O
of O
the O
colon O
leading O
to O
overgrowth O
of O
C B-NonOSE_AE
. I-NonOSE_AE
difficile I-NonOSE_AE
. O

C B-NonOSE_AE
. I-NonOSE_AE
difficile I-NonOSE_AE
produces O
toxins O
A O
and O
B O
which O
contribute O
to O
the O
development O
of O
CDAD B-NonOSE_AE
. O

Hypertoxin O
producing O
strains O
of O
C B-NonOSE_AE
. I-NonOSE_AE
difficile I-NonOSE_AE
cause O
increased O
morbidity O
and O
mortality O
, O
as O
these O
infections O
can O
be O
refractory O
to O
antimicrobial O
therapy O
and O
may O
require O
colectomy O
. O

CDAD B-NonOSE_AE
must O
be O
considered O
in O
all O
patients O
who O
present O
with O
diarrhea B-NonOSE_AE
following O
antibiotic O
use O
. O

Careful O
medical O
history O
is O
necessary O
since O
CDAD B-OSE_Labeled_AE
has O
been O
reported O
to O
occur O
over O
two O
months O
after O
the O
administration O
of O
antibacterial O
agents O
. O

If O
CDAD B-NonOSE_AE
is O
suspected O
or O
confirmed O
, O
ongoing O
antibiotic O
use O
not O
directed O
against O
C B-NonOSE_AE
. I-NonOSE_AE
difficile I-NonOSE_AE
may O
need O
to O
be O
discontinued O
. O

Appropriate O
fluid O
and O
electrolyte O
management O
, O
protein O
supplementation O
, O
antibiotic O
treatment O
of O
C B-NonOSE_AE
. I-NonOSE_AE
difficile I-NonOSE_AE
, O
and O
surgical O
evaluation O
should O
be O
instituted O
as O
clinically O
indicated O
. O

For O
information O
about O
warnings O
of O
other O
drugs O
indicated O
in O
combination O
with O
BIAXIN O
, O
refer O
to O
the O
WARNINGS O
section O
of O
their O
package O
inserts O
. O

Due O
to O
the O
risk O
for O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
clarithromycin O
should O
be O
used O
with O
caution O
in O
patients O
with O
a O
medical O
condition O
associated O
with O
an O
increased O
tendency O
toward O
QT B-Not_AE_Candidate
prolongation I-Not_AE_Candidate
and O
torsades B-Not_AE_Candidate
de I-Not_AE_Candidate
pointes I-Not_AE_Candidate
. O

In O
the O
event O
of O
severe O
acute O
hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
such O
as O
anaphylaxis B-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
drug B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
with I-OSE_Labeled_AE
eosinophilia I-OSE_Labeled_AE
and I-OSE_Labeled_AE
systemic I-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
( I-OSE_Labeled_AE
DRESS I-OSE_Labeled_AE
) O
, O
and O
Henoch B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Schonlein I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
clarithromycin O
therapy O
should O
be O
discontinued O
immediately O
and O
appropriate O
treatment O
should O
be O
urgently O
initiated O
. O

Oral O
Hypoglycemic O
Agents/Insulin O
The O
concomitant O
use O
of O
clarithromycin O
and O
oral O
hypoglycemic O
agents O
and/or O
insulin O
can O
result O
in O
significant O
hypoglycemia B-NonOSE_AE
. O

With O
certain O
hypoglycemic B-NonOSE_AE
drugs O
such O
as O
nateglinide O
, O
pioglitazone O
, O
repaglinide O
and O
rosiglitazone O
, O
inhibition O
of O
CYP3A O
enzyme O
by O
clarithromycin O
may O
be O
involved O
and O
could O
cause O
hypolgycemia B-NonOSE_AE
when O
used O
concomitantly O
. O

Careful O
monitoring O
of O
glucose O
is O
recommended O
. O

Oral O
Anticoagulants O
There O
is O
a O
risk O
of O
serious O
hemorrhage B-NonOSE_AE
and O
significant O
elevations B-NonOSE_AE
in I-NonOSE_AE
INR I-NonOSE_AE
and O
prothrombin O
time O
when O
clarithromycin O
is O
co-administered O
with O
warfarin O
. O

INR O
and O
prothrombin O
times O
should O
be O
frequently O
monitored O
while O
patients O
are O
receiving O
clarithromycin O
and O
oral O
anticoagulants O
concurrently O
. O

HMG-CoA O
Reductase O
Inhibitors O
Concomitant O
use O
of O
clarithromycin O
with O
lovastatin O
or O
simvastatin O
is O
contraindicated O
( O
see O
CONTRAINDICATIONS O
) O
. O

As O
with O
other O
macrolides O
, O
clarithromycin O
has O
been O
reported O
to O
increase O
concentrations O
of O
HMG-CoA O
reductase O
inhibitors O
. O

Rare O
reports O
of O
rhabdomyolysis B-NonOSE_AE
have O
been O
reported O
in O
patients O
taking O
these O
drugs O
concomitantly O
. O

Patients O
should O
be O
monitored O
for O
signs O
and O
symptoms O
of O
myopathy B-NonOSE_AE
. O

Rare O
reports O
of O
rhabdomyolysis B-NonOSE_AE
have O
also O
been O
reported O
in O
patients O
taking O
atorvastatin O
or O
rosuvastatin O
concomitantly O
with O
clarithromycin O
. O

When O
used O
with O
clarithromycin O
, O
atorvastatin O
or O
rosuvastatin O
should O
be O
administered O
in O
the O
lowest O
possible O
doses O
. O

Adjustment O
of O
the O
statin O
dose O
or O
use O
of O
a O
statin O
that O
is O
not O
dependent O
on O
CYP3A O
metabolism O
( O
e.g.fluvastatin O
or O
pravastatin O
) O
should O
be O
considered O
. O

